In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2010

Executive Summary

Biopharma financings slumped in the third quarter of 2010 - the $1.69 billion raised in Q3 was about half of Q2's $3.37 billion. Most of the third quarter money came from VC rounds. Two-thirds of the M&A total came from J&J's $2.2 billion purchase of the 82.1% of Crucell that it didn't already own. And following a long stretch in which earlier-stage assets were grabbing the largest deal values, Q3's biopharma alliances proved the contrary - the majority of the biggest moneymakers were for Phase II and higher therapeutics.
Advertisement

Related Content

Reata's $450 Million Up-Front Haul Sets A Record But Remains An Outlier
Bristol Bid For ZymoGenetics Looks Even Better In Light Of Promising Melanoma Data
Pharma: Serious About Change?
Bristol Bid For ZymoGenetics Looks Even Better In Light Of Promising Melanoma Data
Pharma: Serious About Change?
Reata's $450 Million Up-Front Haul Sets A Record But Remains An Outlier
Immatics Raises €54 Million Series C To Fund Pivotal Therapeutic Cancer Vaccine Trial
Genzyme, J&J Manufacturing Troubles Highlight The Importance Of Quality Systems
Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets
Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003414

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel